TrioxNano

TrioxNano's powerhouse created a biosphere of programmed therapeutic/diagnostic solutions based on synthetic DNA molecular machines Our team of exceptional scientists fluent in the secrets of DNA programming & highly skilled execs has led to the development of the Programmed Medicine Biosphere. Granted global all inclusive patents & winning the prestigious H2020 2.7M grant allowed us develop :

P-ADC - Programmable ADCs (Aptamer DNAzyme Conjugates) Technology: Market Challenges: Analog treatments exhibit low efficacy and high toxicity, addressing only 15% of cancer targets. Our Solution: P-ADC replaces analog components with a digital aptamer and programmed DNAzyme, excelling in highly targeted mRNA knockdown. Market Potential: Estimated at $550B, addressing the growing need for precision medicine.

P-DDP - Programmable Drug Delivery Platforms: Market Challanges: Traditional drug delivery lacks precision, leading to low treatment effectiveness and side effects. Our Solution: P-DDP enables precise drug delivery, significantly improving efficacy and reducing side effects. Market Potential: Estimated at $100B, capitalizing on the demand for personalized medicine.

P-DST - Programmable DNA Strip Technology: Market Challanges: Current antigen tests lack sensitivity, specificity, and home-testing capabilities. Our Solution: P-DST revolutionizes antigen testing with a programmable approach, offering at-home testing for thousands of antigens. Market Potential: Annual revenues estimated at $140B, meeting the increasing demand for accurate home diagnostics.

PCPM - Precision Cancer Profiling using mRNA Knockdown Technology: Market Challanges: Current cancer tests lack functional insights, precision, and cost-effectiveness. Our Solution: PCPM provides functional information, cost-effective mRNA profiling, and AI + ML recommendations for a holistic understanding. Market Potential: Exceeding $100B, addressing the rising need for functional cancer diagnostics.